CD34 and bronchopulmonary dysplasia: For the angiogenesis‐associated markers, a similar trend was present, as there were significant increases in the CD34, CD31 and VEGFA levels in MSC cytotherapy groups compared with the BPD group (Figure 4B, C and D), while there was a significant decrease in CD34 levels in the BPD+BM‐MSC group compared with BPD+AF‐MSC and BPD+UC‐MSC groups.